gfh-genetalks-online.....
Mit dem neuen Format "gfh-genetalks-online" offeriert die GfH allen Mitgliedern und Interessierten eine Kommunikationsplattform, die einmal monatlich – voraussichtlich immer mittwochs – stattfinden soll. In 1 ½ stündigen Sessions präsentieren herausragende Experten unseres Faches ihre wissenschaftlichen Ergebnisse und Highlights, bei denen Sie die Möglichkeit erhalten, in die Diskussion einzusteigen und Fragen zu stellen. Die Teilnahme ist kostenlos. Die Zugangsdaten werden 1 Woche vor der Termin an dieser Stelle bekannt gegeben. Die Auswahl der SprecherInnen und Themen liegt in den Händen der GfH-Programmkommission.
gfh-genetalk-online 4 ..... 21.7.2021 ..... 18:00 - 10:30 Uhr
Prof. Dr. Hildegard Büning: Gene Therapy – Status and Future Direction
As indicated by the 10 market approvals in the Western World, gene therapy has reached the clinical reality. Instead of treating symptoms, gene therapy offers the chance to cure a genetic disease by providing a function gene copy, by counteracting the activity of a malfunctioning gene or – with the advent of genome editing – by repairing the underlying genetic mutation. The range of applications was greatly expanded and currently encompass monogenetic diseases, cancer, and infectious diseases. Despite this success, the full potential of gene therapy has not been fully unlocked so far. Current challenges as well as strategies followed to tackle these challenges will be discussed.
Login-Data: t.b.a.
Prof. Dr. rer.nat. Hildegard Büning
Deputy Director of the Institute of Experimental Hematology, Hannover Medical School,
REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany
Hildegard Büning is Professor of Infection Biology of the Gene Transfer and Deputy Director of the Institute of Experimental Hematology at Hannover Medical School (Hannover, Germany).
She serves as current President of the European Society of Gene and Cell Therapy (www.ESGCT.eu) and Scientific Secretary of the German Society for Gene Therapy (www.dg-gt.de).
She studied Biology in Münster and Munich and obtained her PhD (Dr. rer. nat.) at the Ludwig-Maximilians University Munich in 1997. Since then, she is active in the field of adeno-associated virus (AAV) vectors with a particular focus on AAV-host interactions and AAV vector development. Aiming to optimize efficacy, specificity, and safety of AAV vectors for gene therapy and regenerative medicine, her research team is developing strategies to modify tropism and immunogenicity of AAV vectors using both rational design and library-based approaches.